Global Health / Q3-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Watch2026-02-03Back to MEDANTA

Revenue

₹1,121 Cr

verified against source

Revenue YoY

19%

reported change

EBITDA

₹249.4 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
EBITDA (₹ Cr)PositiveWatchNegative
3 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q2 FY26: 267 · Positive source sentiment · 2025-11-07Q2 FY26Q3 FY26: 249.4 · Watch source sentiment · 2026-02-03Q3 FY26Q4 FY26: 296 · Positive source sentiment · 2026-05-??Q4 FY26296249.4
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Global Health reported Q3 FY26 total income of ₹1,142.8 crore, up 19% YoY, driven by sustained momentum across hospitals. Consolidated EBITDA (including NOIA) stood at ₹249.4 crore with margins of 21.8%, impacted by early-stage losses at the new NOIA hospital (₹320 million EBITDA loss on ₹343 million revenue). PAT was ₹950 million, including a one-time ₹366 million exceptional charge from new labor codes. Mature hospitals grew 9% YoY with 23.9% margins, while developing hospitals (ex-NOIA) grew 22% with 31.7% margins. Management guided for ARP growth of 5-7% annually and expects NOIA losses to moderate as ramp-up continues. Key risk: potential margin pressure from ongoing talent competition and cost inflation.

Colored figures show movement against the previous available record.

Guidance to track

  • Management expects ARP to grow 5-7% per year, with a more conservative internal projection of 3-5%.
  • Next year's capex is expected to be below ₹500 crore, significantly lower than the ~₹1,000 crore in FY26, as major NOIA construction is complete.
  • Management indicated that Q3 losses at NOIA are likely near peak and should reduce as the hospital ramps up.

Risks flagged

  • Management acknowledged a 'war for talent' that could increase employee costs and pressure margins.
  • Analyst raised concerns about insurer-hospital tiffs; management downplayed but noted ongoing commercial negotiations that could impact pricing.
  • Management declined to provide a timeline for NOIA EBITDA breakeven, citing dependence on occupancy and case mix.

Key quotes

  • I hope so that we've seen the peak of the losses.
  • I think that you know 100, 190, 80 basis point swing here and there especially in one period over the other is fairly insignificant.
  • Our goal is to drive this volumes and this business through and through. Once we do that whatever occupancy falls out of that it falls out of that.

Research modules

Go one layer deeper.